General Investing >> Analyst Interviews >> March 15, 2004


ROBERT NELSEN is Managing Director and Co-Founder of ARCH Venture Partners. ARCH Venture Partners is one of the US's leading early-stage technology venture capital firms, with over $900 million under management. Mr. Nelsen concentrates on new company creation from early stage technologies originating from universities and national laboratories with a special concentration in life sciences. He led the formation and initial funding round of Everyday Learning Corporation, Adolor Corporation, Netbot, Inc. and Optobionics Corporation. Mr. Nelsen was also responsible for ARCH's early investments in Aviron, Inc., Caliper Life Seciences, Illumina, Inc., deCode Genetics,Inc., GenVec, Inc., Genomica Corporation, Alnylam, Inc., Xenoport, Inc., Neurogesx, Inc., Xcyte Therapies, Inc., R2 Technology, Inc., Elixir, Array BioPharma, Inc., Trubion, Inc., Surface Logix and Amphora. Mr. Nelsen is a past or present director of Adolor Corporation Caliper Life Sciences (CALP), Xcyte Therapies, Inc., Illumina, Inc. (ILMN), Everyday Learning Corporation, and was Chairman of Netbot, Inc. He holds a BS in Biology and Economics from The University of Puget Sound and an MBA from The University of Chicago. Profile
TWST: What is ARCH Venture Partners and what are its recent activities?

Mr. Nelsen: ARCH is an early-stage technology investor, probably one of

the more early-stage investors in the world '